Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Palmitoylethanolamide (PEA) vs Placebo for Major Depression: a Phase II Exploratory Study

NCT06063369 is registered in ClinicalTrials.gov with The Israeli Medical Center for Alzheimer's as lead sponsor.

NCT NCT06063369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06063369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Palmitoylethanolamide (PEA) vs Placebo for Major Depression: a Phase II Exploratory Study
Lead sponsor
The Israeli Medical Center for Alzheimer's
Phase
Phase 2
Overall status
Unknown status
Start date
December 21, 2022
Completion date
December 21, 2024
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression, major depressive disorder